Indications and side effects of plasma and plasma products
**Indications and side effects of plasma and plasma products**

**Actual use of plasma:**

<table>
<thead>
<tr>
<th>Procedure/clinical indication</th>
<th>Percentage of FFP transfusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>33.3%</td>
</tr>
<tr>
<td>Warfarin reversal</td>
<td>20.2%</td>
</tr>
<tr>
<td>Other coagulopathy</td>
<td>14.3%</td>
</tr>
<tr>
<td>Before invasive procedure</td>
<td>5.9%</td>
</tr>
<tr>
<td>Bleed</td>
<td>8.4%</td>
</tr>
<tr>
<td>Massive transfusion</td>
<td>7.3%</td>
</tr>
<tr>
<td>Plasma exchange</td>
<td>3.8%</td>
</tr>
<tr>
<td>Trauma</td>
<td>0.3%</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>6.3%</td>
</tr>
</tbody>
</table>

>50% acute situations

Indications and side effects of plasma and plasma products

Actual use of plasma:

55% of plasma transfusions could be qualified as appropriate based on internationally agreed-upon indications, with fully 28% qualifying as inappropriate and the remainder as indeterminate.

Indications and side effects of plasma and plasma products

Available types of plasma:

**Quarantined Fresh Frozen Plasma (Q-FFP)**
- Apheresis plasma (from one donor) stored in quarantine for six months
- Donor tested for certain diseases during donation; retested 6 months later (window period)
- Plasma released for use if donor clears second round of testing & given to patient
- Expiry: 3-36 months after donation (depending on storage temperature)

Blood tests:
- HIV, HBV, HCV, Syphilis, HTLV-I/II

![Diagram showing the process of plasma donation, testing, and storage.](image)
Indications and side effects of plasma and plasma products

Pathogen reduction methods:

- Industrial methods
  - Immune neutralisation
  - Solvent/detergent treatment
  - Heat treatment
  - Low pH treatment

- Others
  - Photochemical treatment

M. Schipperus, MD/PhD
Indications and side effects of plasma and plasma products

Available types of plasma:

**INTERCEPT Plasma (Amotosalen Inactivated)**
- Apheresis plasma (from one donor)
- Units processed using INTERCEPT pathogen reduction system in-house
- Can be used with either freshly collected or frozen plasma which has been recently thawed

Blood tests:
HIV, HBV, HCV, Syphilis, HTLV-I/II
Indications and side effects of plasma and plasma products

Available types of plasma:

**Mirasol® Plasma (Riboflavin + UV Inactivated)**
- Apheresis plasma (from one donor)
- Units processed using Mirasol pathogen reduction system in-house
- Can be used with either freshly collected or frozen plasma which has been recently thawed

Blood tests: HIV, HBV, HCV, Syphilis, HTLV-I/II
Indications and side effects of plasma and plasma products

Available types of plasma:

**THERAFLEX Plasma (Methylene Blue Inactivated)**
- Apheresis plasma (from one donor) or whole blood
- Units processed using THERAFLEX pathogen reduction system in-house
- Can be used with either freshly collected or frozen plasma which has been recently thawed

**Blood tests:**
- HIV, HBV, HCV, Syphilis, HTLV-I/II
**Indications and side effects of plasma and plasma products**

**Available types of plasma:**

**Solvent/Detergent treated pooled Plasma (SDP) – e.g. Octaplas™, Omniplasma™ (TNBP + Triton X-100)**
- Plasma from ~1000 donors pooled
- Pool undergoes pathogen inactivation process
- Plasma separated into individual bags of uniform composition

Blood tests:
- HIV, HBV, HCV, Syphilis, HTLV-I/II
- HAV, Parvo* (non-enveloped)

*Test is done to confirm presence of antibodies against these viruses.
Indications and side effects of plasma and plasma products

Effect of filtration:

Fresh-frozen plasma → Cell and debris free

Octaplas® → Cell and debris free
Indications and side effects of plasma and plasma products

Effect of filtration:

- Optimised integration
- Cell removal & S/D treatment & removal
- Optimised integration
- Cell removal
- TRALI
- Allergic rx. (urticaria)
Indications and side effects of plasma and plasma products

Table 1: Usage of various plasma types across European countries

<table>
<thead>
<tr>
<th>Land (jaarrapport)</th>
<th>Q-FFP</th>
<th>SDP</th>
<th>MB-plasma</th>
<th>Amotosalen</th>
<th>Riboflavine</th>
<th>Totaal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duitsland (2009)</td>
<td>1.066.000</td>
<td>65.000</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>1.131.000</td>
</tr>
<tr>
<td>Frankrijk (2009)</td>
<td>1.400</td>
<td>142.000</td>
<td>205.000</td>
<td>23.000</td>
<td>*</td>
<td>371.400</td>
</tr>
<tr>
<td>VK (2009)</td>
<td>307.000</td>
<td>53.000</td>
<td></td>
<td></td>
<td></td>
<td>360.000</td>
</tr>
<tr>
<td>Nederland (2009)</td>
<td>90.000</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>90.000</td>
</tr>
<tr>
<td>België (2006)</td>
<td>*</td>
<td>*</td>
<td>66.000</td>
<td>*</td>
<td>*</td>
<td>66.000</td>
</tr>
<tr>
<td>Denemarken (2008)</td>
<td>62.000</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>62.000</td>
</tr>
<tr>
<td>Noorwegen (2008)</td>
<td>*</td>
<td>48.000</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>48.000</td>
</tr>
<tr>
<td>Finland (2007)</td>
<td>*</td>
<td>46.000</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>46.000</td>
</tr>
<tr>
<td>Totaal</td>
<td>1.526.400</td>
<td>354.000</td>
<td>271.000</td>
<td>23.000</td>
<td></td>
<td>2.174.400</td>
</tr>
</tbody>
</table>

* niet vermeld in het Jaarrapport
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:

- Allergic/Anaphylactic reactions
- Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)
- Hemolytic transfusion reactions (via RBC alloimmunization)
- Septic transfusion reactions
- Transfusion Related Acute Lung Injury (TRALI)
- Transfusion Associated Circulatory Overload (TACO)
- Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)
- Hyperfibrinolysis
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:

• Allergic/Anaphylactic reactions
  *By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.*

• Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)

• Hemolytic transfusion reactions (via RBC alloimmunization)

• Septic transfusion reactions

• Transfusion Related Acute Lung Injury (TRALI)

• Transfusion Associated Circulatory Overload (TACO)

• Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)

• Hyperfibrinolysis
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:
• Allergic/Anaphylactic reactions
  By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.
• Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)
  Results in fever with or without signs of allergic response. Definitions vary between countries, but is typically defined as an increase in temperature of 1-2°C not otherwise explained.
• Hemolytic transfusion reactions (via RBC alloimmunization)
• Septic transfusion reactions
• Transfusion Related Acute Lung Injury (TRALI)
• Transfusion Associated Circulatory Overload (TACO)
• Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)
• Hyperfibrinolysis
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:

- **Allergic/Anaphylactic reactions**
  By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.

- **Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)**
  Results in fever with or without signs of allergic response. Definitions vary between countries, but is typically defined as an increase in temperature of 1-2°C not otherwise explained.

- **Hemolytic transfusion reactions (via RBC alloimmunization)**
  Presents with fever, hypotension and oliguria – requires immediate cessation.

- **Septic transfusion reactions**

- **Transfusion Related Acute Lung Injury (TRALI)**

- **Transfusion Associated Circulatory Overload (TACO)**

- **Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)**

- **Hyperfibrinolysis**
Plasma transfusions carry the risk of adverse events, including but not limited to:

- **Allergic/Anaphylactic reactions**
  By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.

- **Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)**
  Results in fever with or without signs of allergic response. Definitions vary between countries, but is typically defined as an increase in temperature of 1-2°C not otherwise explained.

- **Hemolytic transfusion reactions** (via RBC alloimmunization)
  Presents with fever, hypotension and oliguria – requires immediate cessation.

- **Septic transfusion reactions**
  Presents with fever, hypotension within minutes of transfusion start – requires immediate cessation.

- **Transfusion Related Acute Lung Injury (TRALI)**

- **Transfusion Associated Circulatory Overload (TACO)**

- **Venous Thromboembolism** (both Deep Venous Thrombosis and Pulmonary Embolism)

- **Hyperfibrinolysis**
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:

• Allergic/Anaphylactic reactions
  *By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.*

• Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)
  *Results in fever with or without signs of allergic response. Definitions vary between countries, but is typically defined as an increase in temperature of 1-2°C not otherwise explained.*

• Hemolytic transfusion reactions (via RBC alloimmunization)
  *Presents with fever, hypotension and oliguria – requires immediate cessation.*

• Septic transfusion reactions
  *Presents with fever, hypotension within minutes of transfusion start – requires immediate cessation.*

• Transfusion Related Acute Lung Injury (TRALI)
  *Presents with bilateral pulmonary edema, dyspnea. #1 cause of plasma transfusion associated mortality*

• Transfusion Associated Circulatory Overload (TACO)

• Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)

• Hyperfibrinolysis
Indications and side effects of plasma and plasma products

Plasma transfusions carry the risk of adverse events, including but not limited to:

- **Allergic/Anaphylactic reactions**
  *By far the most common reaction. Presents with urticaria and symptoms of general malaise. In rare cases of anaphylaxis, hypotension and stridor present, requiring immediate attention.*

- **Febrile Non-Hemolytic Transfusion Reactions (FNHTRs)**
  *Results in fever with or without signs of allergic response. Definitions vary between countries, but is typically defined as an increase in temperature of 1-2°C not otherwise explained.*

- **Hemolytic transfusion reactions (via RBC alloimmunization)**
  *Presents with fever, hypotension and oliguria – requires immediate cessation.*

- **Septic transfusion reactions**
  *Presents with fever, hypotension within minutes of transfusion start – requires immediate cessation.*

- **Transfusion Related Acute Lung Injury (TRALI)**
  *Presents with bilateral pulmonary edema, dyspnea. #1 cause of plasma transfusion associated mortality*

- **Transfusion Associated Circulatory Overload (TACO)**
  *Presents with hypertension and dyspnea owing to resulting pulmonary edema*

- **Venous Thromboembolism (both Deep Venous Thrombosis and Pulmonary Embolism)**
- **Hyperfibrinolysis**

The presence of both of these as possible side effects indicates plasma transfusions can lead to both hyper and hypocoagulative states.
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

**Solvent/Detergent treated pooled Plasma**
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

**Single Donor Plasmas (Quarantined, AI, MB)**
Cheaper per mL

Risk of emerging pathogen transmission

Nominal levels of coagulation proteins
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

**Solvent/Detergent treated pooled Plasma**
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

**Single Donor Plasmas (Quarantined, AI, MB)**
Cheaper per mL

Nominal levels of coagulation proteins
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

Solvent/Detergent treated pooled Plasma
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

Single Donor Plasmas (Quarantined, AI, MB)
Cheaper per mL

Nominal levels of coagulation proteins

The rate of allergic/anaphylactic reactions when transfusing SDP is between 76% and 94% lower than that of FFP*


M. Schipperus, MD/PhD
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

- **Solvent/Detergent treated pooled Plasma**
  Consistent plasma protein levels

- Fewer allergic/anaphylactic reactions

- **No Transfusion Related Acute Lung Injury**

- More effective (smaller volume needed)

- **Single Donor Plasmas (Quarantined, AI, MB)**
  Cheaper per mL

- Nominal levels of coagulation proteins

Since its introduction, there has yet to be a confirmed case of TRALI following SDP transfusion*


M. Schipperus, MD/PhD
Effect of the male-only measure

PAR: 0.33 (95% CI 0.09 to 0.51)
Excl. “possible TRALI”: 0.37 (0.06 – 0.58)

Wiersum-Osselton et al, Transfusion,
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

**Solvent/Detergent treated pooled Plasma**
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

**Single Donor Plasmas (Quarantined, AI, MB)**
Cheaper per mL

Nominal levels of coagulation proteins

Total volume of plasma transfused decreased by 16.2% following replacement of Q-FFP with SDP in Finland (2006-2009 data)*

Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

Solvent/Detergent treated pooled Plasma
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

Single Donor Plasmas (Quarantined, AI, MB)
Cheaper per mL

Nominal levels of coagulation proteins

Prices vary per country, but SDP tends to be around 25% more expensive by volume.

*Sanquin Bloedvoorziening, 2012, Plasma Assortiment, Sanquin Bloedvoorziening, Amsterdam, the Netherlands.
Indications and side effects of plasma and plasma products

SDP vs. Q-FFP – advantages:

**Solvent/Detergent treated pooled Plasma**
Consistent plasma protein levels

Fewer allergic/anaphylactic reactions

No Transfusion Related Acute Lung Injury

More effective (smaller volume needed)

**Single Donor Plasmas (Quarantined, AI, MB)**
Cheaper per mL

Nominal levels of coagulation proteins

SDP has reduced levels of the following plasma proteins:

- Protein S
- $\alpha_2$-antiplasmin
- Factor V
- Factor VII

...the lack of Protein S and $\alpha_2$-antiplasmin are particularly important as they have been suggested to lead to rather serious side effects:

Low Protein S levels:
**VTE during TTP treatment using SDP**

Low $\alpha_2$-antiplasmin levels:
**Hyperfibrinolysis during OLT using SDP**

M. Schipperus, MD/PhD
**Indications and side effects of plasma and plasma products**

**FDA requests of studies required for final approval of Octaplas:**

1. A study to investigate the incidence of hyperfibrinolysis during OLT following use of SDP:

2. A study to investigate the incidence of DVT and PE following repeated SDP transfusions during TTP treatment:

   www.clinicaltrial.gov : Not yet recruiting
Octaplas:

------------------------ WARNINGS AND PRECAUTIONS ------------------------

• Transfusion reactions can occur with AB0 blood group mismatches (5.1)
• High infusion rates can induce hypervolemia with consequent pulmonary edema or cardiac failure (5.2)
• Excessive bleedings due to hyperfibrinolysis can occur due to low levels of alpha2-antiplasmin (5.3)
• Thrombosis can occur due to low levels of Protein S (5.4)
• Citrate toxicity can occur with volumes exceeding one milliliter of Octaplas per kg per minute (5.5)
• Octaplas is made from human blood; therefore, may carry the risk of transmitting infectious agents, e.g., viruses and theoretically, the variant Creutzfeldt-Jakob disease and Creutzfeldt-Jakob disease agent (5.6)
Indications and side effects of plasma and plasma products

Incidences of plasma transfusion related adverse events (AEs):

- Reported incidences of most common AEs vary by orders of magnitude

- Reasons for inconsistency of reported incidences include:
  - Most plasma transfusions take place in acute settings
  - Presenting symptoms of most common (allergic) reactions are subtle
  - Definitions of FNHTRs vary by country (sometimes even by hospital)
  - Pre-medication of patients hampers observation of many common AEs

- Plasma Transfusion related AEs remain both costly and potentially fatal
Indications and side effects of plasma and plasma products

FROSTED study:
FResh frozen plasma, Omniplasma, & SDP comparison of Transfusion reactions, Efficacy and DVT study

• 2-year Dutch study currently in progress
• Goals of study include:
  - *International comparison of AE incidences for various plasma sorts*
  - *Evaluation of Omniplasma™ with regard to AEs, efficacy and DVT*
  - *Estimation of under-diagnosis of plasma transfusion related AEs*
Indications and side effects of plasma and plasma products

With thanks to:
- Tom Krusius, Finnish Red Cross
- Nic Saadeh, Leiden University Medical Center

Questions?